Search results

Slides from a recent presentation by Prof Morten, the second half is mostly about this work. Near the end there is a slide about their next step on this project: This seems like a much more sensible approach than what they did in the paper. Good to see them trying to replicate in multiple...

I think the fact that they are looking at an objective outcome (ATG-13 in serum) makes it different, especially if they can correlate ATG-13 with severity before treatment begins (it would also be great if they did more work to compare ATG-13 in patients and healthy controls, since all they have...

I imagine Simmaron simply does not have the resources to do a full trial with a control group (their annual revenue is about half a million dollars), so they are doing this trial which looks like it basically collects data from a few doctors who are prescribing it. They are collecting data on...

That's definitely not what the paper says though. Seems like Dr. Kaplan misread the paper, to start with. In it, they report 21 patients reported PEM after a CPET or 18 in the abstract (not clear why these are different). But not all of the 43 patients had a CPET and it isn't clear how many...

That was in a question to Nath, maybe it was just confusion on the part of the asker.

Just going off the content of these tweets, I think the idea is that there is antigen (could be persistent antigen from past infection or could be some kind of autoimmune situation), but not active infection. But it doesn't sound like they've found any particular antigen, so it's all just a...

Isn't it interesting that out of their 25 healthy controls, only after the third round of screening did they discover that one had MS, one had early-onset dementia and one had meningitis?

This part of their exploratory outcomes seems interesting: "Cross-referencing heart rate patterns with participant-provided symptoms and diagnoses to identify correlations; identify underlying signals in surveys and/or wearable data that may help differentiate those who will recover within six...

FWIW, Nath's hypothesis seems to be: "(Our) hypothesis of persistent antigen as (cause of ME) is based on immune markers. That made us wonder if persistent antigen--whether host or foreign--that's what made us make that hypothesis." "We hypothesize--one possibility that there is persistent...

Hilary Johnson is tweeting notes from some of the sessions (Nath and Hanson): Nath: (Conclusion) we think all our findings suggest persistent antigen leads to immune dysfunction and microbial dysbiosi in GI tract. Neuroimmune axis gets dysregulation, contributing to metabolic abnormalities...

Amazingly, all that machine learning and all those Network Medicine models came up with LDN and Mestinon, which were surely invisible to conventional analysis. It would really be nice is OMF communications weren't so obviously fake.

I think the weight for ME just doesn't exist officially in the WHO list. This Danish study, based on a questionnaire, came up with 0.47, while this study references an Australian report that calculated 0.14, 0.45 and 0.76 for mild, moderate and severe CFS (for comparison WHO says mild, moderate...

This thread has me thinking that I need to introduce some blinding into my own trials of medications. I think this would not do much for some drugs, which have obvious side effects, but could be worthwhile for others. I'm imagining buying some opaque capsules, crushing up some pills (for...

The number of patients and controls is so small that it is hard to make much of this, but given the pretty significant difference seen here (which looks to be more than could be explained by sex differences alone) and the sensible mechanistic connection between ME symptoms and plasma glucose and...

I love this: No change in the objective symptoms, but since the patients could now complete the test, they must be improved.

Some interesting points made about one of the author on Twitter, seems reasonable to me to assume there could be some level of (undisclosed) AI writing involved in this. Another of the authors is an editor at the journal it was published in (which makes no sense for the topic). Seems pretty sketchy.

He, unfortunately given his huge audience, so consistently posts incorrect summaries of papers he clearly hasn't read on Twitter, that it's hard to take him seriously any more.

OMF posted an update on the Kynurenine trial at some point: IRB approval has been obtained and trial conducted in healthy volunteers. Paper published. [paper] Analysis of preliminary data for ME/CFS patients did not indicate significant disturbances in the Kynurenine pathway so further trials...

I'm searching for pulmonary vascular capacitance and finding that it seems to be defined as stroke volume divided by pulse pressure, but here they seem to be defining it as stroke volume times pulse pressure. Not clear why. Without a full study to look at here, my worry would be that, even if...

"the treatment group (n=37, dose range: 24-360mg/d) demonstrated a significant increase in oxygen uptake efficiency slope (OUES) (T0: 1.82 ± 0.56, T1: 1.98 ± 0.53; p=0.044) [...] These differences were not observed in the control group (n=16) OUES (T0: 1.62 ± 0.40, T1: 1.77 ± 0.47; p=0.268)"...